Ignite Creation Date:
2024-05-06 @ 12:45 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01642940
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2012-07-12
Brief Title:
Ī¤icagrelor Versus Prasugrel in Diabetic Patients a Pharmacodynamic Study
Sponsor:
University of Patras
Organization:
University of Patras
Study Overview
Official Title:
Ī¤icagrelor Versus Prasugrel in Diabetic Patients a Pharmacodynamic Study
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective randomized single-center single blind investigator initiated two period study of crossover design Diabetic patients with Acute Coronary Syndrome ACS treated with oral andor parenteral hypoglycaemic therapy for at least 1 month and subjected to percutaneous coronary intervention PCI will be randomized after a baseline platelet reactivity PR assessment 24 hours post PCI while under clopidogrel in a 11 ratio to either prasugrel 10mg or ticagrelor 180mg for 15 days followed by crossover directly to the alternate therapy for an additional 15 days without an intervening washout period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None